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Metformin is the first-line treatment for type 2 diabetes
(T2D). Although widely prescribed, the glucose-lowering
mechanism for metformin is incompletely understood.
Here, we used a genome-wide association approach in
a diverse group of individuals with T2D from the Action to
Control Cardiovascular Risk inDiabetes (ACCORD) clinical
trial to identify common and rare variants associated with
HbA1c response to metformin treatment and followed up
these findings in four replication cohorts. Common var-
iants inPRPF31andCPA6were associatedwithworse and
bettermetformin response, respectively (P < 53 1026), and
meta-analysis in independent cohorts displayed similar
associations with metformin response (P = 1.2 3 1028
and P = 0.005, respectively). Previous studies have shown
that PRPF31(+/2) knockout mice have increased total
body fat (P = 1.783 1026) and increased fasted circulating
glucose (P = 5.73 3 1026). Furthermore, rare variants in
STAT3 associatedwithworsemetformin response (q <0.1).
STAT3 is a ubiquitously expressed pleiotropic transcrip-
tional activator that participates in the regulation of me-
tabolism and feeding behavior. Here, we provide novel
evidence for associations of common and rare variants
in PRPF31, CPA6, and STAT3 with metformin response
that may provide insight into mechanisms important
for metformin efficacy in T2D.
The incidence of type 2 diabetes (T2D) is increasing and the
Centers for Disease Control and Prevention estimate that
11% of U.S. adults, aged 20 years or older, have diagnosed or
undiagnosed T2D, and 35% of people in the same age-group
have prediabetes based on fasting glucose or hemoglobin A1c
(HbA1c) levels (1). T2D is now considered a global epidemic
with prevalence increasing from 108 million in 1980 to
422 million in 2014 (2). Individuals with T2D are at an
increased risk of developing blindness and kidney failure and
are at risk for lower-limb amputations. Furthermore, indi-
viduals with T2D are 2–4 times more likely to develop
cardiovascular disease (CVD), including heart attack and
stroke (3).
Metformin, a member of the biguanide class of drugs, is
now considered first-line therapy for individuals with T2D
(4). Despite intensive investigation, the molecular mecha-
nisms mediating metformin’s beneficial effects on glycemic
control remain controversial and poorly understood. Studies
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be found in Fig. 1. Additional demographic information can
be found in Table 1.
Phenotype Definitions
Glycemic response to metformin was evaluated in subjects
who began taking metformin while enrolled in ACCORD;
subjects who reported taking metformin or another bigua-
nide prior to enrollment in the trial were excluded. Some
subjects were taking additional medications and were
accounted for as described in the Supplementary Data and
Graham et al. (18). Subjects were scheduled for study visits
every 1 or 4 months based on randomization to the inten-
sive or standard glycemia arms, respectively. HbA1c was
recorded every 4 months. Metformin response was calcu-
lated as on-treatment HbA1c minus pretreatment HbA1c.
Pretreatment HbA1c levels were recorded no more than
30 days prior to the start of metformin. On-treatment
HbA1c levels were defined as the first recordedmeasurement
acquired after at least 90 days and no more than 270 days
from the start of metformin treatment. This interval was
chosen to allow for HbA1c levels to stabilize after starting
metformin, while limiting changes in glycemia levels due to
additional modifications to treatment regimens. Medication
compliance and other details regarding the phenotype def-
inition can be found in the Supplementary Data.
Genotyping
Briefly, 6,085 unique samples from ACCORD participants
who consented to genetic studies conducted by any inves-
tigator were genotyped at the University of Virginia on
Illumina HumanOmniExpressExome-8 v1.0 chips (Set 1);
8,174 unique samples, including the above 6,085 samples
plus 2,089 samples from ACCORD participants who con-
sented to genetic studies only if conducted by ACCORD
investigators, were genotyped at the University of North
Carolina on Affymetrix Axiom Biobank1 chips (Set 2). The
data were then merged, resulting in one data set consisting
of 5,971 samples genotyped at a total of 1,240,656 in-
dividual SNPs, and another with an additional 2,083 samples
genotyped at 583,613 SNPs. Additional details can be found
in the Supplementary Data and Marvel et al. (19).
Data Processing
Covariate Selection
We implemented a variable selection procedure to address
potential confounding. Some variables were included in the
model based on previous studies or expert knowledge,
whereas other variables were selected based on a backward
selection approach and Bayesian information criteria to
identify covariates specific to the ACCORD data set. All
covariate names and descriptions before variable selection
can be found in Supplementary Table 1. A substantial pro-
portion of the cohort was taking other medications dur-
ing the metformin treatment response time frame and
these concomitant medications were incorporated into the
model as described in the Supplementary Data. To prevent
confounding due to population substructure, principal
performed predominantly in animal models have implicated 
various mechanisms and molecules as participating in 
metformin’s beneficial effects, including direct inhibitory 
effects on mitochondrial function, activation of hepatic 
AMPK, and  alterations in glucagon signaling pathways  
(5–10). The relative importance of these mechanisms for 
metformin’s beneficial effects on glycemic control in humans 
is unclear.
There is significant interindividual variability in response 
to metformin (11–13). This suggests that a better under-
standing of the mechanisms by which metformin functions 
might allow for more tailored and precise treatment. Studies 
suggest that heritable factors contribute to this variability, 
which provides an opportunity to identify causal genetic 
contributors through genetic association studies (11). Recent 
genome-wide association studies (GWAS) have identified 
common variants that affected metformin response in the 
ATM locus, which has been shown to activate AMPK, and the 
SLC2A2 locus, which encodes the facilitated glucose trans-
porter, GLUT2 (12,13). Here, we use a GWAS approach in 
a large cohort of individuals with T2D in the Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) clinical 
trial to test for associations of both common and rare variant 
single nucleotide polymorphisms (SNPs) with change in 
HbA1c in response to metformin treatment.
The ACCORD trial followed 10,251 participants for up to 
8 years at 77 clinical centers in the U.S. and Canada to 
compare the benefits and risks of treatment strategies for 
intensively targeting glycemia, blood pressure, and dyslipi-
demia versus standard targets in individuals with T2D at 
high risk for CVD (14–17). No overall benefit and possible 
harms were observed in the combined primary CVD end 
points with intensive glucose-lowering therapy. However, 
significant variability in treatment response was also ob-
served, highlighting the potential for identifying genetic 
markers of drug response that may lead to the development 
of improved and personalized treatment strategies. The 
results presented here point to novel mechanisms of met-
formin drug response and potential therapeutic targets for 
the treatment of T2D.
RESEARCH DESIGN AND METHODS
Study Participants
The ACCORD trial (ClinicalTrials.gov identifier: NCT00000620) 
was a double 2 3 2 factorial design comparing intensive 
versus standard treatment approaches for controlling gly-
cemia, blood pressure, and dyslipidemia that enrolled 10,251 
patients with T2D with a history of CVD or at least two 
known risk factors for CVD, such as documented athero-
sclerosis, albuminuria, dyslipidemia, hypertension, smoking, 
or obesity (14). Additional details about randomization and 
selection criteria for the various arms of the ACCORD trial 
can be found in the Supplementary Data. Participants in 
ACCORD were given an option to provide a blood sample for 
future genetic studies, and over 80% of participants agreed 
to do so. A workflow describing the selection of subjects can
component analysis was performed based on the genotype
data using EIGENSTRAT (v4.2) and is described in the
Supplementary Data. The final models after covariate selec-
tion can be found in Supplementary Tables 2–4. A workflow
detailing each step of the analysis can be found in Supple-
mentary Fig. 4.
Common Variant Analysis
Associations between a phenotype, covariates, and single
common variant (minor allele frequency [MAF] .3%) were
tested using the linear regression model. Genotyped variants
were tested as an additive variable using PLINK, where
gi   ∈  f0; 1; 2g is the number of minor alleles for the
ith individual. Imputed variants were tested using a linear
regression model in the statistical programming language, R,
where gi ¼ piðAaÞ þ 2piðaaÞ is the dosage score computed
from the posterior probabilities for genotypes Aa and aa
(20). For SNPs that were only genotyped in Set 1 subjects
and were imputed in Set 2 subjects, association tests were
calculated for each set separately and the results were
Figure 1—Studydesign andquality control (QC)workflow.Boxes represent the steps taken in theworkflow. The number of remaining subjects after
a quality control step can be found in the relevant attached circle.
combined by meta-analysis using PLINK (21,22). Tables and
figures specify whether each result derives from a SNP that
was genotyped in all subjects, imputed in all subjects, or
represents a combination of genotyped and imputed data
using the meta-analysis approach described.
Rare Variant Analysis
The rare variant analysis approach has been previously
described (19). Briefly, all variants (MAF#3%)weremapped
to gene annotation from Ensemble (GRCh37.p13). A suite of
five rare variant tests comprised of burden and nonburden
were then used to assess associations with metformin re-
sponse. We combined the set of five P values from each test
into a single P value for each gene using the procedure
described by Dai et al. (23). Subsequently, the combined
P value was corrected for multiple comparisons with a false
discovery rate approach (24,25), and a threshold of q ,0.1
was used for statistical significance.
Replication of ACCORD Results
SNPs that associated with metformin response in the com-
mon variant analyses (P , 5 3 1026) were tested for
associations in the following cohorts. There was one cohort
from European ancestry, which included combined samples
from Genetics of Diabetes Audit and Research in Tayside
Scotland (GoDARTS) and PMET1-EU (Pharmacogenomics of
Metformin, cohort 1, of European ancestry; PMET1 was
previously named PMT2) (REP1) (n = 6,963). Therewere two
cohorts fromAfrican American ancestry, referred to as REP2
(n = 646) and REP3 (n = 369). Briefly, the GoDARTS cohort
in REP1 has been described before by theWellcome Trust Case
Control Consortium 2 (13). The REP2 cohort was collected
from two main clinical sites, Kaiser Permanente Northern
California and Kaiser Permanente South East, as previously
described (26). The PMET1-EU in REP1 and the REP3
cohorts were collected from the Research Program on
Genes, Environment and Health (RPGEH), based at Kaiser
Permanente Northern California (27). Metformin response
for REP1 was defined as pretreatment HbA1c minus post-
treatment HbA1c, resulting in effects that are in the opposite
direction of those in ACCORD. Because of this, the additive
inverse of effect sizes in REP1 was used in the analysis with
ACCORD results. For REP2 andREP3,metformin responsewas
calculated as posttreatmentHbA1cminus pretreatmentHbA1c.
To provide additional support for the role of the lead
SNP, rs57081354, in modulating metformin action, we
performed an association test between rs57081354 and
baseline HbA1c in ACCORD individuals that were already
on metformin at the start of the trial (REP4) and compared







Intensive glycemia arm 56.33 59.41 53.15
Standard glycemia arm 43.67 40.59 46.85
Intensive blood pressure arm 23.86 23.67 34.23
Standard blood pressure arm 23.78 21.89 33.33
Fibrate lipid treatment arm 25.99 25.68 14.41
Placebo lipid treatment arm 26.37 28.76 18.01
Female 39.48 36.33 52.70
Age (mean [95% CI]) 62.72 [62.36, 63.10] 63.14 [62.70, 63.58] 62.25 [61.37, 63.12]
BMI (mean [95% CI]) 32.43 [32.13, 32.73] 33.18 [32.82, 33.54] 32.67 [31.94, 33.39]
Years with T2D (mean [95% CI]) 10.10 [9.67, 10.51] 9.73 [9.23, 10.24] 10.82 [9.76, 11.87]
History of cardiovascular disease 33.54 35.27 29.28
Concomitant medications*
Angiotensin type 2 antagonists 16.39 15.98 16.67
ACE inhibitors 46.19 46.98 52.25
a-Glucosidase inhibitors 0.53 0.47 0.45
Cholesterol absorption inhibitors 2.13 2.49 1.80
Statin 49.70 51.83 30.18
Lisinopril 16.46 16.45 25.23
Loop diuretics 8.23 8.99 10.36
Meglitinides 2.97 2.37 3.15
Nitrates 5.72 6.51 3.60
Other diabetes treatments 2.67 2.84 4.05
Sulfonylureas 52.44 51.83 45.05
Thiazolidinediones 31.63 33.02 29.28
Insulin 38.11 38.11 45.95
Data are %, unless stated otherwise. *Tabulated percentages represent the percentage of subjects with at least one record of taking
themedication or amedication in the drug class during themetformin treatment window. This is not an exhaustive list of medications recorded
in ACCORD, but rather a representative list of the commonly used medications in ACCORD.
those results to the association of baseline HbA1c in
individuals not on metformin at the start of the trial. All
individuals in REP4 were excluded from the discovery cohort
due to the lack of a recorded pretreatment HbA1c, making it
impossible to calculate a change in HbA1c with treatment.
For this analysis, an association test was performed as
described in the common variant analysis with the exception
of the phenotype being baseline level of HbA1c rather than
change in HbA1c.
Each SNP with P , 5 3 1028 in the discovery cohort or
with P , 5 3 1026 in the discovery cohort and q ,0.01 in
at least one replication cohort were meta-analyzed across
available cohorts using PLINK (21,22). Meta-analysis with
P , 0.05 was considered to be statistically significant. Ad-
ditional information regarding each cohort can be found
in the Supplementary Data, and a workflow describing how
the replicationwas evaluated can be found in Supplementary
Fig. 4.
Dietary Analysis
Dietary questionnaires were assessed for 1,600 participants
that both consented to genotyping and had dietary records
as part of the Health-Related Quality of Life substudy with-
in ACCORD. Scores in response to the dietary questionnaires
were tested for association with the lead SNP, rs57081354,
using a linear regression model and the same covariate
selection process as described above. Details regarding this
analysis can be found in the Supplementary Data.
RESULTS
A total of 1,312, 845, and 222 subjects were included in the
common and rare variant analyses for all races combined,
white, and black cohorts, respectively (Fig. 1). Other racial
groups were included in the all races combined group, but
sample sizes were too small to perform stratified analyses.
Variation was observed inHbA1c response (Fig. 2). Themean
change in HbA1c was21.42% (95% CI21.49,21.36) for all
races combined,21.47% (21.55,21.39) for white subjects
only, and 21.35% (21.50, 21.19) for black subjects only.
The difference in the change in HbA1c between white and
black subjects was not statistically significant (P = 0.16).
Variables selected as being significantly associated with
metformin response explained approximately 55% of the
variation in metformin response and were subsequently
included in the common and rare variant analyses (Supple-
mentary Tables 2–4). Briefly, assignment to the intensive
glycemia arm of the ACCORD trial, years with T2D, and
pretreatment HbA1c were significantly associated with met-
formin response in all tested groups.
Common Variant Analysis
A total of 316,203 genotyped, 547,639 meta-analyzed, and
7,567,403 imputed variants had MAF .3% and were in-
cluded in the common variant analysis when all races were
combined. A total of 1, 3, and 7 SNPs were significantly
associated with HbA1c response in all races combined, white
subjects only, and black subjects only, respectively (P, 53
1028). In all subjects combined, the lead SNP rs57081354
located within an intron in the NBEA gene associated with
HbA1c response (Fig. 3). Sixty-five SNPs in 16 loci on
14 different chromosomes (in genes NBEA, LOC105374140,
CXCL13,MCC, FAM189A1, LOC107984525, LOC105379109,
KIAA1024, RBFOX1, LOC643339, UBOX5, NR2C1, BPHL,
PRPF31, LOC105377165, and ADAMTS9-AS2) reached the
threshold for suggestive significance (P , 5 3 1026). For
white subjects only, 3 SNPs in KIAA1024 were associated
with HbA1c response at genome-wide levels of significance
(P, 5 3 1028), and 23 SNPs in 7 loci (in genes KIAA1024,
LOC283177, LOC105377165, ADAMTS9-AS2, CPA6,NR2C1,
and DPYD) reached the threshold for suggestive significance
(P , 5 3 1026) (Supplementary Fig. 1). When black sub-
jects were analyzed separately, 2 SNPs in the LOC102724874
locus were associated with HbA1c response at genome-wide
levels (P , 5 3 1028), and 53 SNPs in 8 loci (in genes
LOC102724874, LOC105374308, LOC105369406, SLC35D3,
RHPN2, ETS1, SDK2, and GPC6) reached the threshold for
suggestive significance (P , 5 3 1026) (Supplementary
Fig. 2). Lead SNPs associated with HbA1c response (P, 53
1026) are presented in Tables 2–4.
Rare Variant Analysis
Rare variants (MAF #0.03) in a total of 17,078 genes were
tested for association with HbA1c in all subjects combined
and separately in white and black subjects. In the combined
subject analysis, rare variants in STAT3 were significantly
associated with HbA1c response (q ,0.1) (Supplementary
Fig. 3). Five rare variants were available for testing in STAT3:
rs146620441 (monomorphic), rs140604473 (missense),
rs149214040 (missense), rs114401618 (intronic),
and rs17882069 (synonymous) (28). Importantly,
rs146620441 was monomorphic and the other four
SNPs only showed variation in black subjects, although
there were no statistically significant rare variant associ-
ations observed in race-based analyses (q.0.2). We tested
whether STAT3 failed to yield significant associations in the
stratified analysis due to the small number of black subjects
(n = 222) by oversampling black subjects until we had the
same number of subjects as when all races were com-
bined (n = 1,312). Oversampling to build a larger cohort
resulted in a q = 0.0016 versus a q = 1 in the original cohort
of black subjects, supporting the premise that this rare
variant finding is relevant for black subjects even though
it was detected when all subjects were combined due to an
increase in statistical power.
Association With Dietary Phenotypes
NBEA has been previously reported to influence sugary food
preference in animal models (29), and we further assessed
whether the lead SNP in this locus, rs57081354, was associated
with dietary scores. Data were available in 1,553 ACCORD
subjects (Supplementary Table 6). The C-allele in rs57081354
that associated with worse metformin effect also asso-
ciated with increased consumption of dessert (q = 0.12).
Subjects with the C-allele in rs57081354 were more likely
to answer “Yes” to the question, “Did you eat dessert?”
within past 3 months (b = 0.044 [95% CI 0.012, 0.075]).
Replication
A total of 134 unique SNPs were associated with metformin
response (P , 5 3 1026) when all races were combined, in
white subjects only, and in black subjects only. Of these
SNPs, 81, 64, and 61 were available in REP1, REP2, and
REP3 cohorts, respectively. The most significant finding in
the discovery cohort was rs57081354 located in the NBEA
gene (P = 4.02 3 1028, b = 0.323). This finding did not
replicate in REP1 (P. 0.05) and was not available for testing
in REP2 or REP3. Out of the 26 SNPs in NBEA with P, 13
1026, only rs1337379 was tested in REP2 and REP3 but was
not associated with metformin response (P. 0.05). SNPs in
NBEA were not significantly associated with metformin
response in ACCORD when black or white subjects were
tested separately, only when all races were combined. Inter-
estingly, in the set of subjects who were already on metfor-
min when they enrolled in ACCORD (REP4), rs57081354,
was marginally associated with higher baseline HbA1c (P =
0.09), whereas rs57081354 was not associated with base-
line variation in HbA1c in those not onmetformin (P = 0.63).
Although the phenotypes for REP1 and REP4 are not
Figure 2—Distributions of HbA1c response to metformin treatment. A: HbA1c response when all races are combined. B: HbA1c response in only
white participants. C: HbA1c response in only black participants.
identical, meta-analysis of the ACCORD discovery cohort
with REP1 and REP4 produced an association representing
higher HbA1c on metformin (P = 0.009) (Fig. 3).
In ACCORD, rs254271, located in an intron in pre-mRNA
processing factor 31 (PRPF31), was associated with worse
metformin response when all races were combined
(P = 3.79 3 1026). In the REP1 cohort, rs254271 was
associated with worse metformin response when corrected
for baseline HbA1c (P = 6.213 10
25) and without adjusting
for baselineHbA1c (P = 1.573 10
22). Genotypes for rs254271
were not available for analysis in the African American
replication cohorts, REP2 and REP3. Meta-analysis of ACCORD
with REP1 produced a significant association for rs254271
with worse metformin response (P = 1.2 3 1028) (Fig. 4).
In white subjects in ACCORD, rs2162145, located in
carboxypeptidase A6 (CPA6), was associated with better
metformin response (P = 4.04 3 1026). This finding was
consistent with findings in African American subjects in
REP2 (P = 0.006). Although, rs2162145 was not significantly
associated with metformin response in black subjects in
ACCORD (P = 0.14), it is possible that we were underpow-
ered to detect an association due to the relatively small
number of black subjects available (n = 222) and that meta-
analysis could increase statistical power through the inclu-
sion of additional subjects. Meta-analysis of black subjects in
ACCORD and those in REP2 and REP3 demonstrated the
most significant association of rs2162145 with better met-
formin response (P = 0.005) compared with meta-analysis of
all white subjects (ACCORDwhite subjects and REP1) and all
cohorts (ACCORD, REP1–3) with P = 0.22 and P = 0.09,
respectively (Fig. 4).
DISCUSSION
T2D adversely affects the quality of life for millions of
individuals and places a significant burden on the health
care system in the U.S. and globally (30,31). Although many
treatment options for T2D are available, metformin has
remained the first-line treatment for T2D for decades.
Nevertheless, the mechanisms by which metformin lowers
blood glucose are not well understood, and factors that may
Figure 3—HbA1c response tometformin treatment is diminished by SNPs inNBEA. A: Manhattan plot of HbA1c response to metformin treatment
when all raceswere combined (N= 1,312). The horizontal dashed lines represent suggestive statistical significance (P= 53 1026) (bottom line) and
genome-wide significance (P=531028) (top line). Eachpoint representsa single SNP.GenotypedSNPs are representedwith black dots, imputed
SNPs are represented by blue dots, and SNPs meta-analyzed from subjects genotyped in Set 1 subjects and imputed in Set 2 subjects are
represented by pink dots.B: A LocusZoom (48) plot demonstrating the leadSNP, rs57081354, associationwith change inHbA1cwhen all races are
combined. Linkage disequilibrium was calculated using the 1000 Genomes reference panel using the hg19/1000 Genomes Nov 2014 EUR
selection, matching the panel used to perform imputation in ACCORD. C: Forest plot demonstrating associations of rs57081354 in available
replication cohorts. The b values for REP1were changed to the additive inverse tomaintain a consistent direction of effect. A larger b valuemeans
a diminishedmetformin response. Data for rs57081354were not available for REP2 andREP3. Bars represent the 95%CIs.D: Change inHbA1c by





























































































































































































































































































































































































predict which patients will have optimal responses to met-
formin are also not well understood. Here, we use a GWAS
approach in a large cohort of individuals with T2D in the
ACCORD clinical trial to test for both common and rare
variant SNPs that associate with change in HbA1c level in
response to metformin treatment. To support our initial
findings, we explored these associations in multiple inde-
pendent cohorts.
A previous study conducted in a large cohort using
electronic medical records found that African American
patients on metformin had a larger reduction in HbA1c
than European Americans (32).We failed to find a significant
difference between metformin response in white subjects
and black subjects in ACCORD, with changes in HbA1c
of21.47% and21.35%, respectively (P = 0.16). It is possible
that enrollment in a more structured clinical trial impacts
these outcomes differently than the far less structured care
reflected in electronic medical record data. Additional re-
search will be needed to definitely characterize the response
of metformin across ethnicities. Previous GWAS have iden-
tified rs11212617 in the ATM locus and rs8192675 in
SLC2A2 as being significantly associated with metformin
response (12,13). However, neither SNP was significantly
associated with metformin response here (P . 0.1). These
SNPs may have failed to replicate in the current study due to
cohort differences and, in particular, the sample size of the
ACCORD cohort and the use of concomitant medications.
Information regarding the prescribed dose for metformin was
not recorded in ACCORD and may have impacted our find-
ings. However, as described in RESEARCH DESIGN AND METHODS,
we sought a minimal time window to assess the response
ofmetforminwhile limiting the likelihood of othermedication
changes. Additional details about how these studies compare
with ACCORD can be found in the Supplementary Data.
In the analysis of subjects from all racial groups combined
(n = 1,312) (Fig. 1), those with the C-allele of rs254271, an
intronic variant in PRPF31, had a worse metformin response
at suggestive significance levels (P = 3.793 1026, b = 0.16).
The effect of this variant was also observed in REP1,
consisting of subjects of European ancestry (P = 6.21 3
1025, b =20.073). Interestingly, rs254271 is an expression
quantitative trait locus in several tissues for PRPF31 and
nearby genes, including NADH:ubiquinone oxidoreductase
(NDUFA3), which codes for a subunit of the complex I of
the respiratory chain (33–35). Metformin is known to in-
hibit complex I of the respiratory chain to cause AMPK
activation (5). In addition, previous studies have shown that
PRPF31(+/2) knockout mice have increased total body fat
(P = 1.78 3 1026) and increased fasted circulating glucose
(P = 5.73 3 1026) (36).
Genotypes for rs254271 were not available for analysis in
the African American replication cohorts, REP2 and REP3.
The phenotype in REP1 represents HbA1c reduction, so the
direction of the effect for rs254271 is consistent between
ACCORD and REP1 and represents worse HbA1c response in
individuals with the C-allele (Fig. 4). Mutations in PRPF31























































































































































































































































































































































































































































































































































































































































































































































































































Figure 4—Forest plot of associations with replicated SNPs in REP1, REP2, and REP3.A: Discovery and replication results for rs2162145, located
in theCPA6 gene.B: Discovery and replication results for rs254271, an intronic variant inPRPF31. A larger b valuemeans a diminishedmetformin
response. The b values for REP1 were changed to the additive inverse to maintain a consistent direction of effect. Bars represent the
95% CIs.
in the stratified analysis likely due to the small number
of subjects available for analysis (n = 222). In this same
cohort, rare variants in STAT3 were not associated with
baseline HbA1c levels (q .0.2). STAT3 encodes a ubiqui-
tously expressed transcription factor with broad activities
in metabolism, immunity, and cell growth (43). STAT3 is
an essential signal transducer for the key metabolic hor-
mone leptin and the pleiotropic cytokine interleukin 6 with
broad effects on feeding behavior and fuel homeostasis.
Interestingly, metformin has been shown to interact with
STAT3 signaling in chemotherapeutic applications and in an
inflammatory bowel diseasemodel (44–47). To our knowledge,
interactions between metformin and STAT3 signaling have
not been investigated with regard to glucose homeostasis.
Here, we present evidence for PRPF31, CPA6, and STAT3
being involved in novel glucose-lowering mechanisms for
metformin. Additional investigation will also be required to
confirm the clinical impact of the identified variants with
regard to metformin therapy in subjects with diabetes.
Although prior studies suggest roles for NBEA and STAT3
genes in glucose metabolism, additional research will be
required to investigate mechanisms by which they might
interact with metformin. Such studies are likely to provide
new insight into mechanisms regulating glucose metabolism
and may point the way toward novel therapeutic targets for
more precise interventions in T2D.
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